{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:15:46Z","timestamp":1785284146316,"version":"3.55.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.oftal.2014.09.011","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T15:35:04Z","timestamp":1416238504000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Uso off-label de bevacizumab intrav\u00edtreo en retinopat\u00eda del prematuro severa"],"prefix":"10.1016","volume":"90","author":[{"given":"L.E.","family":"Alba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Zaldua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftal.2014.09.011_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","article-title":"Treatment of retinopathy of prematurity with vascular endothelial growth factor","volume":"88","author":"Mintz-Hitner","year":"2012","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.oftal.2014.09.011_bib0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/0301-4738.62644","article-title":"Results of screening for retinopathy of prematurity in a large nursery in Kuwait: Incidence and risk factors","volume":"58","author":"Wani","year":"2010","journal-title":"Indian J Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clp.2013.02.001","article-title":"Retinopathy of prematurity-incidence today","volume":"40","author":"Zin","year":"2013","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4103\/0301-4738.33057","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"55","author":"Azad","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0025","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone 2","volume":"28","author":"Mintz-Hitner","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.oftal.2014.09.011_bib0035","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.oftal.2014.09.011_bib0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.oftal.2014.09.011_bib0045","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0036933013496933","article-title":"Intravitreal bevacizumab for the treatment of retinopathy of prematurity: A case report","volume":"58","author":"Flavahan","year":"2013","journal-title":"Scott Med J"},{"key":"10.1016\/j.oftal.2014.09.011_bib0055","first-page":"50","article-title":"Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab","author":"Goldman","year":"2013","journal-title":"J Pediatr Ophthalmol Strabismus."},{"key":"10.1016\/j.oftal.2014.09.011_bib0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","article-title":"Current and future trends in treatment of severe retinopathy of prematurity","volume":"40","author":"Wallace","year":"2013","journal-title":"Clin Perinatol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0065","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bjo.2007.126201","article-title":"Retinopathy of prematurity in the United States","volume":"92","author":"Lad","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0070","first-page":"237","article-title":"DOG (German Ophthalmological Society): Retinopathy of prematurity best possible treatment. Antibody therapy - only advisable in certain cases","volume":"31","author":"Voormann","year":"2012","journal-title":"Kinderkrankenschwester."},{"key":"10.1016\/j.oftal.2014.09.011_bib0075","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1891\/0730-0832.31.4.242","article-title":"Bevacizumab (avastin) for the treatment of retinopathy of prematurity","volume":"31","author":"Beaulieu","year":"2012","journal-title":"Neonatal Netw."},{"key":"10.1016\/j.oftal.2014.09.011_bib0080","first-page":"101","article-title":"Oxigen-induced rethinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oftal.2014.09.011_bib0085","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endotelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinophaty of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.oftal.2014.09.011_bib0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.6061\/clinics\/2012(01)10","article-title":"Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after shortterm treatment with intravitreous bevacizumab","volume":"67","author":"Fusco","year":"2012","journal-title":"Clinics (Sao Paulo)."},{"key":"10.1016\/j.oftal.2014.09.011_bib0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/02713683.2011.611609","article-title":"Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors","volume":"37","author":"Rabinowitz","year":"2012","journal-title":"Curr Eye Res."},{"key":"10.1016\/j.oftal.2014.09.011_bib0100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3109\/02713683.2012.669003","article-title":"Avastin treatment reduces retinal neovascularization in a mouse model of retinopathy of prematurity","volume":"37","author":"Rabinowitz","year":"2012","journal-title":"Curr Eye Res."},{"key":"10.1016\/j.oftal.2014.09.011_bib0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157339909787314121","article-title":"Intravitreal bevacizumab for diabetic retinopathy","volume":"5","author":"Arevalo","year":"2009","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.oftal.2014.09.011_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-008-0952-y","article-title":"A systematic review on the effect of bevacizumab age-related macular degeneration","volume":"247","author":"Schouten","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"Suppl 4","key":"10.1016\/j.oftal.2014.09.011_bib0115","first-page":"S70","article-title":"Intravitreal bevacizumab injection in advanced retinopathy of prematurity","volume":"95","author":"Choovuthakom","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.oftal.2014.09.011_bib0120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ped.12124","article-title":"Intravitreal bevacizumab monotherapy for retinopathy of prematurity","volume":"55","author":"\u015eahin","year":"2013","journal-title":"Pediatr Int."},{"key":"10.1016\/j.oftal.2014.09.011_bib0125","first-page":"160","article-title":"Intravitreal bevacizumab as single drug therapy for retinopathy of prematurity in 12 patients","volume":"112","author":"Bancalari","year":"2014","journal-title":"Arch Argent Pediatr."},{"key":"10.1016\/j.oftal.2014.09.011_bib0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","article-title":"Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? O\u2019Keefe M, Lanigan B, Long VW. Outcomes of zona I retinopathy of prematurity","volume":"91","author":"Spandau","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5301\/ejo.5000176","article-title":"Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial","volume":"22","author":"Mintz-Hittner","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/IAE.0b013e318296e26d","article-title":"Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity","volume":"34","author":"Kim","year":"2014","journal-title":"Retina."},{"key":"10.1016\/j.oftal.2014.09.011_bib0145","first-page":"170","article-title":"Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series","volume":"91","author":"Dani","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","article-title":"Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"Patel","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0155","first-page":"65","article-title":"Present-day conservative treatment retinopathy of prematurity","volume":"115","author":"Monika","year":"2013","journal-title":"Klin Oczna."},{"key":"10.1016\/j.oftal.2014.09.011_bib0160","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of the child: Understanding retinopathy of prematurity through ROP: The Fiedenwald lecture","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oftal.2014.09.011_bib0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of criotherapy for retinopathy of prematuririty: Preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oftal.2014.09.011_bib0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjophthalmol-2011-300573","article-title":"Experts do not agree when to treat retinopathy of prematurity based on plus disease","volume":"96","author":"Slidsborg","year":"2012","journal-title":"Br J Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0180","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1167\/iovs.12-11492","article-title":"A murine model for retinopathy of prematurity identifies endothelial cell proliferation as a potential mechanism for plus disease","volume":"54","author":"Guaiquil","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"10.1016\/j.oftal.2014.09.011_bib0185","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Supression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.oftal.2014.09.011_bib0190","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1073\/pnas.93.10.4851","article-title":"Oligodeoxidenucleotides inhibit retinal neovascularization in a murine model of proliferative retinophaty","volume":"93","author":"Robinson","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.oftal.2014.09.011_bib0195","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/OPTH.S31016","article-title":"Emerging roles for antiangiogenesis factors in management of ocular disease","volume":"6","author":"Saeed","year":"2013","journal-title":"Clin Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0200","first-page":"29","article-title":"Effect of intravitreal pegaptanib or bevacizumab and laser treatment of threshold retinopathy of prematurity in zone I and posterior zone II-four years results","volume":"68","author":"Autrata","year":"2012","journal-title":"Cesk Slov Oftalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0205","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of premeturity","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos Schwartz","year":"2013","journal-title":"Retina."},{"key":"10.1016\/j.oftal.2014.09.011_bib0215","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0220","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftal.2014.09.011_bib0225","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3928\/01913913-20120821-03","article-title":"An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: Part 1. Retinopathy of prematurity","volume":"49","author":"Mititelu","year":"2012","journal-title":"J Pediatr Ophthalmol Strabismus."},{"key":"10.1016\/j.oftal.2014.09.011_bib0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mpa.2000.107904","article-title":"Zone I retinopathy of prematurity","volume":"4","author":"Katz","year":"2000","journal-title":"J Aapos"},{"key":"10.1016\/j.oftal.2014.09.011_bib0235","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0161-6420(01)00540-1","article-title":"The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP)","volume":"108","author":"Good","year":"2001","journal-title":"Ophthalmology"},{"issue":"4 Suppl","key":"10.1016\/j.oftal.2014.09.011_bib0240","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","article-title":"Aggressive posterior retinopathy of prematurity","volume":"30","author":"Drenser","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oftal.2014.09.011_bib0245","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajo.2006.05.048","article-title":"Early vitreous surgery for aggressive posterior retinopathy of prematurity","volume":"142","author":"Azuma","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0250","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ajo.2007.10.027","article-title":"Evolution of retinal detachment in posterior retinopathy of prematurity: Impact on treatment approach","volume":"145","author":"Vinekar","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0255","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevazcizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hitner","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.oftal.2014.09.011_bib0260","doi-asserted-by":"crossref","first-page":"s13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinophaty of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"issue":"4 Suppl","key":"10.1016\/j.oftal.2014.09.011_bib0265","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin)","volume":"30","author":"Dorta","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oftal.2014.09.011_bib0270","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0275","first-page":"e304","article-title":"Acta Ophthalmol","volume":"91","author":"Xu","year":"2013","journal-title":"Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection."},{"key":"10.1016\/j.oftal.2014.09.011_bib0280","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentration of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0285","first-page":"3","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment-a review","volume":"52","author":"Hard","year":"2011","journal-title":"Acta Pediatr"},{"key":"10.1016\/j.oftal.2014.09.011_bib0290","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0295","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis."},{"key":"10.1016\/j.oftal.2014.09.011_bib0300","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature."},{"key":"10.1016\/j.oftal.2014.09.011_bib0305","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMe1100248","article-title":"Bevacizumab for retinophaty of prematurity","volume":"364","author":"Reynolds","year":"2011","journal-title":"N England J Med"},{"key":"10.1016\/j.oftal.2014.09.011_bib0310","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1136\/archdischild-2013-303933","article-title":"Management of retinopathy of prematurity","volume":"98","author":"Fleck","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"key":"10.1016\/j.oftal.2014.09.011_bib0315","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","article-title":"VEGF is required for growth and survival in neonatal mice","volume":"126","author":"Gerber","year":"1999","journal-title":"Development."},{"key":"10.1016\/j.oftal.2014.09.011_bib0320","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI119416","article-title":"Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis","volume":"99","author":"Kitamoto","year":"1997","journal-title":"J Clin Invest."},{"key":"10.1016\/j.oftal.2014.09.011_bib0325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/019262339902700115","article-title":"Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody","volume":"27","author":"Ryan","year":"1999","journal-title":"Toxicol Pathol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","article-title":"The expanding role of vascular endothelial growth factor inhibitors in ophthalmology","volume":"87","author":"Michael","year":"2012","journal-title":"May Clin Proc."},{"key":"10.1016\/j.oftal.2014.09.011_bib0335","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.1167\/iovs.11-8479","article-title":"Will the BEAT-ROP Study results really beat ROP?","volume":"52","author":"Raizada","year":"2011","journal-title":"Invest OphthalmolVis Sci"},{"key":"10.1016\/j.oftal.2014.09.011_bib0340","article-title":"Choroidal ischemia secondary to a single IVB injection for the treatment of AP-ROP could be an unusual complication which raises the concern of its use as a monotherapy in neonates","author":"Chablani","year":"2013","journal-title":"Semin Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0345","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","article-title":"Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2013","journal-title":"J AAPOS."},{"key":"10.1016\/j.oftal.2014.09.011_bib0350","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity","volume":"26","author":"Lee","year":"2012","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.oftal.2014.09.011_bib0355","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10384-012-0141-8","article-title":"Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: A case report","volume":"56","author":"Sun","year":"2012","journal-title":"Jpn J Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0360","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitrealbevacizumab for retinopathy of prematurity","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oftal.2014.09.011_bib0365","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","article-title":"Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian twin cities retinopathy of prematurity screening database. Report number 5","volume":"98","author":"Jalali","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"key":"10.1016\/j.oftal.2014.09.011_bib0370","article-title":"What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?","author":"Spandau","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0375","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","author":"Harder","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0380","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/jop.2011.0060","article-title":"Intravitreal bevacizumab for retinopathy of prematurity","volume":"27","author":"Harder","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.oftal.2014.09.011_bib0385","doi-asserted-by":"crossref","DOI":"10.1007\/s10384-014-0310-z","article-title":"Intravitreal injection of bevacizumab for retinopathy of prematurity","author":"Kuniyoshi","year":"2014","journal-title":"Jpn J Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0390","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: Incorporating the BEAT-ROP results into clinical practice","volume":"118","author":"Moshfeghi","year":"2011","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftal.2014.09.011_bib0395","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"10.1016\/j.oftal.2014.09.011_bib0400","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija SG1","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0405","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3928\/0191-3913-20060301-07","article-title":"Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity","volume":"43","author":"Ng","year":"2006","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.oftal.2014.09.011_bib0410","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3928\/0191-3913-20060301-04","article-title":"Fundus fluorescein angiography in retinopathy of prematurity","volume":"43","author":"Wagner","year":"2006","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.oftal.2014.09.011_bib0415","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","author":"Henaine-Berra","year":"2014","journal-title":"J AAPOS."},{"key":"10.1016\/j.oftal.2014.09.011_bib0420","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archophthalmol.2012.1","article-title":"Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"Harder","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oftal.2014.09.011_bib0425","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3928\/01913913-20120731-03","article-title":"Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab","volume":"49","author":"Tseng","year":"2012","journal-title":"J Pediatr Ophthalmol Strabismus."}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669114003566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669114003566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T18:09:03Z","timestamp":1650650943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365669114003566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0365669114003566"],"URL":"https:\/\/doi.org\/10.1016\/j.oftal.2014.09.011","relation":{},"ISSN":["0365-6691"],"issn-type":[{"value":"0365-6691","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uso off-label de bevacizumab intrav\u00edtreo en retinopat\u00eda del prematuro severa","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2014.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}